Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference26 articles.
1. Opportunities for improving the therapeutic ratio for patients with sarcoma;Wunder;The Lancet Oncol,2007
2. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor;Heinrich;J Clin Oncol,2003
3. Induction of angiogenesis during the transition from hyperplasia to neoplasia;Folkman;Nature,1989
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis;Hanahan;Cell,1996
5. Targeting angiogenesis for the treatment of sarcoma;Balasubramanian;Curr Opin in Oncol,2006
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08
2. Disease-Modifying Effects of Lenvatinib, a Multiple Receptor Tyrosine Kinase Inhibitor, on Posttraumatic Osteoarthritis of the Knee;International Journal of Molecular Sciences;2024-06-13
3. Sanshimao formula inhibits the hypoxia-induced pro-angiogenesis of hepatocellular carcinoma cells partly through regulating MKK6/p38 signaling pathway;Journal of Pharmacy and Pharmacology;2024-01-30
4. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16
5. Effects of Hochuekkito on Lenvatinib-Induced Fatigue in Mice;BPB Reports;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3